GRANT PICKERING - 16 May 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Executive Officer, Director
Signature
Grant Pickering, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
16 May 2022
Net transactions value
-$243,300
Form type
4
Filing time
18 May 2022, 16:39:55 UTC
Previous filing
20 Apr 2022
Next filing
27 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $19,690 +11,000 +1.6% $1.79 714,894 16 May 2022 Direct
transaction PCVX Common Stock Sale $186,896 -7,866 -1.1% $23.76 707,028 16 May 2022 Direct F1, F2
transaction PCVX Common Stock Sale $76,094 -3,134 -0.44% $24.28 703,894 16 May 2022 Direct F1, F3
holding PCVX Common Stock 355,660 16 May 2022 By Children's Trusts

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -11,000 -4.5% $0.000000 234,450 16 May 2022 Common Stock 11,000 $1.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $23.17 to $24.16. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.17 to $24.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The shares subject to the option are fully vested and exercisable.